Valproic Acid Solution
FDA Label NDC 0116-4021

29 label sections · Submitted to the FDA by Xttrium Laboratories Inc. · Indications, Dosage, Usage, and Precautions

Structured Product Label

The following Structured Product Label (SPL) was submitted to the FDA by Xttrium Laboratories Inc. for the product Valproic Acid (NDC 0116-4021). This document serves as the official prescribing information, containing essential scientific data and clinical materials required for healthcare providers and patients.

This specific version of the label includes detailed information regarding highlights of prescribing information, indications and usage, dosage and administration, dosage forms and strength, contraindications, warnings and precautions, adverse reactions, drug insteractions, and other regulatory disclosures. Use the navigation below to review specific sections of the FDA submission.

10 Overdosage

Overdosage with valproate may result in somnolence, heart block, deep coma, and hypernatremia. Fatalities have been reported; however, patients have recovered from valproate levels as high as 2,120 mcg/mL.

In overdose situations, the fraction of drug not bound to protein is high and hemodialysis or tandem hemodialysis plus hemoperfusion may result in significant removal of drug. The benefit of gastric lavage or emesis will vary with the time since ingestion. General supportive measures should be applied with particular attention to the maintenance of adequate urinary output.

Naloxone has been reported to reverse the CNS depressant effects of valproate overdosage. Because naloxone could theoretically also reverse the antiepileptic effects of valproate, it should be used with caution in patients with epilepsy.

11 Description

Valproic acid is a carboxylic acid designated as 2-propylpentanoic acid. It is also known  as dipropylacetic acid. Valproic acid has the following structure:

Valproic-01 (56e26840 53bd 4a3f Bd32 5a03fe373a3a 01)

Valproic-01 (56e26840 53bd 4a3f Bd32 5a03fe373a3a 01)

Valproic acid (pKa 4.8) has a molecular weight of 144 and occurs as a colorless liquid  with a characteristic odor. It is slightly soluble in water (1.3 mg/mL) and very soluble in organic solvents.

Valproic Acid Oral Solution is an antiepileptic for oral administration. The oral solution contains the equivalent of 250 mg valproic acid per 5 mL as the sodium salt.

14 Clinical Studies

The studies described in the following section were conducted using divalproex sodium tablets.

14.1 Epilepsy

The efficacy of divalproex sodium in reducing the incidence of complex partial seizures (CPS) that occur in isolation or in association with other seizure types was established in two controlled trials.

In one, multi-clinic, placebo controlled study employing an add-on design (adjunctive therapy), 144 patients who continued to suffer eight or more CPS per 8 weeks during an 8 week period of monotherapy with doses of either carbamazepine or phenytoin sufficient to assure plasma concentrations within the "therapeutic range" were randomized to receive, in addition to their original antiepilepsy drug (AED), either divalproex sodium or placebo. Randomized patients were to be followed for a total of 16 weeks. The following table presents the findings.

Table 5. Adjunctive Therapy Study Median Incidence of CPS per 8 Weeks
Add-on Treatment
Number of Patients
Baseline Incidence
Experimental Incidence
Divalproex sodium
75
16.0
8.9

Reduction from baseline statistically significantly greater for divalproex sodium than placebo at p ≤ 0.05 level.


Placebo
69
14.5
11.5

Figure 1 presents the proportion of patients (X axis) whose percentage reduction from baseline in complex partial seizure rates was at least as great as that indicated on the Y axis in the adjunctive therapy study. A positive percent reduction indicates an improvement (i.e., a decrease in seizure frequency), while a negative percent reduction indicates worsening. Thus, in a display of this type, the curve for an effective treatment is shifted to the left of the curve for placebo. This figure shows that the proportion of patients achieving any particular level of improvement was consistently higher for divalproex sodium than for placebo. For example, 45% of patients treated with divalproex sodium had a ≥ 50% reduction in complex partial seizure rate compared to 23% of patients treated with placebo.

Figure 1

Valproic-02 (56e26840 53bd 4a3f Bd32 5a03fe373a3a 02)

Valproic-02 (56e26840 53bd 4a3f Bd32 5a03fe373a3a 02)

The second study assessed the capacity of divalproex sodium to reduce the incidence of CPS when administered as the sole AED. The study compared the incidence of CPS among patients randomized to either a high or low dose treatment arm. Patients qualified for entry into the randomized comparison phase of this study only if 1) they continued to experience 2 or more CPS per 4 weeks during an 8 to 12 week long period of monotherapy with adequate doses of an AED (i.e., phenytoin, carbamazepine, phenobarbital, or primidone) and 2) they made a successful transition over a two week interval to divalproex sodium. Patients entering the randomized phase were then brought to their assigned target dose, gradually tapered off their concomitant AED and followed for an interval as long as 22 weeks. Less than 50% of the patients randomized, however, completed the study. In patients converted to divalproex sodium monotherapy, the mean total valproate concentrations during monotherapy were 71 and 123 mcg/mL in the low dose and high dose groups, respectively.

The following table presents the findings for all patients randomized who had at least one post-randomization assessment.

Table 6. Monotherapy Study Median Incidence of CPS per 8 Weeks
Treatment
Number of Patients
Baseline Incidence
Randomized Phase Incidence
High dose divalproex sodium
131
13.2
10.7

Reduction from baseline statistically significantly greater for high dose than low dose at p ≤ 0.05 level.


Low dose divalproex sodium
134
14.2
13.8

Figure 2 presents the proportion of patients (X axis) whose percentage reduction from baseline in complex partial seizure rates was at least as great as that indicated on the Y axis in the monotherapy study. A positive percent reduction indicates an improvement (i.e., a decrease in seizure frequency), while a negative percent reduction indicates worsening. Thus, in a display of this type, the curve for a more effective treatment is shifted to the left of the curve for a less effective treatment. This figure shows that the proportion of patients achieving any particular level of reduction was consistently higher for high dose divalproex sodium than for low dose divalproex sodium. For example, when switching from carbamazepine, phenytoin, phenobarbital or primidone monotherapy to high dose divalproex sodium monotherapy, 63% of patients experienced no change or a reduction in complex partial seizure rates compared to 54% of patients receiving low dose divalproex sodium.

Figure 2

Information on pediatric studies is presented in section 8.

Valproic-03 (56e26840 53bd 4a3f Bd32 5a03fe373a3a 03)

Valproic-03 (56e26840 53bd 4a3f Bd32 5a03fe373a3a 03)

15 References

1Meador KJ, Baker GA, Browning N, et al. Fetal antiepileptic drug exposure and  cognitive outcomes at age 6 years (NEAD study): a prospective observational study. Lancet Neurology 2013; 12 (3):244–252.

16 How Supplied/Storage And Handling

Valproic Acid Oral Solution, USP is available as a clear, cherry-flavored red oral solution containing the equivalent of 250 mg of valproic acid per 5 mL as the sodium salt in the following oral dosage forms:

16 fl oz (473 mL) bottles (NDC 0116-4021-16).

5 mL unit dose cups (NDC 0116-4021-05) packaged in trays of 10 unit dose cups each with either 4 or 10 trays to a case

10 mL unit dose cups (NDC 0116-4021-10) packaged in trays of 10 unit dose cups each with 10 trays to a case

RECOMMENDED STORAGE

Store at 20°–25°C (68°–77°F) [See USP Controlled Room Temperature]. Dispense in a tight, light-resistant container as defined in the USP, with child-resistant closure.

17 Patient Counseling Information

Advise the patient to read the FDA-approved patient labeling (Medication Guide).

Medication Guide

Valproic Acid Oral Solution

Read this Medication Guide before you start taking valproic acid oral solution and each time you get a refill. There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition or treatment.

What is the most important information I should know about valproic acid oral solution?

Do not stop taking valproic acid oral solution without first talking to your healthcare provider.

Stopping valproic acid oral solution suddenly can cause serious problems.

Valproic acid oral solution can cause serious side effects, including:

1. Serious liver damage that can cause death, especially in children younger than 2 years old.

The risk of getting this serious liver damage is more likely to happen within the first 6 months of treatment.

Call your healthcare provider right away if you get any of the following symptoms:

  • nausea or vomiting that does not go away
  • loss of appetite
  • pain on the right side of your stomach (abdomen)
  • dark urine
  • swelling of your face
  • yellowing of your skin or the whites of your eyes
  • In some cases, liver damage may continue despite stopping the drug.

    2. Valproic acid oral solution may harm your unborn baby.

    • If you take valproic acid oral solution during pregnancy for any medical condition, your baby is at risk for serious birth defects that affect the brain and spinal cord and are called spina bifida or neural tube defects. These defects occur in 1 to 2 out of every 100 babies born to mothers who use this medicine during pregnancy. These defects can begin in the first month, even before you know you are pregnant. Other birth defects that affect the structures of the heart, head, arms, legs, and the opening where the urine comes out (urethra) on the bottom of the penis can also happen. Decreased hearing or hearing loss can also happen.
    • Birth defects may occur even in children born to women who are not taking any medicines and do not have other risk factors.
    • Taking folic acid supplements before getting pregnant and during early pregnancy can lower the chance of having a baby with a neural tube defect.
    • If you take valproic acid oral solution during pregnancy for any medical condition, your child is at risk for having a lower IQ and may be at risk for developing autism or attention deficit/hyperactivity disorder.
    • There may be other medicines to treat your condition that have a lower chance of causing birth defects, decreased IQ, or other disorders in your child.
    • Women who are pregnant must not take valproic acid oral solution to prevent migraine headaches.
    • All women of child-bearing age (including girls from the start of puberty)should talk to their healthcare provider about using other possible treatments instead of valproic acid oral solution. If the decision is made to use valproic acid oral solution, you should use effective birth control (contraception).
    • Tell your healthcare provider right away if you become pregnant while taking valproic acid oral solution. You and your healthcare provider should decide if you will continue to take valproic acid oral solution while you are pregnant.
    • Pregnancy Registry: If you become pregnant while taking valproic acid oral solution, talk to your healthcare provider about registering with the North American Antiepileptic Drug Pregnancy Registry. You can enroll in this registry by calling toll-free 1-888-233-2334 or by visiting the website, http://www.aedpregnancyregistry.org/. The purpose of this registry is to collect information about the safety of antiepilectic drugs during pregnancy.
    • 3. Inflammation of your pancreas that can cause death.

      Call your healthcare provider right away if you have any of these symptoms:

      • severe stomach pain that you may also feel in your back
      • nausea or vomiting that does not go away
      • 4. Like other antiepileptic drugs, valproic acid oral solution may cause suicidal thoughts or actions in a very small number of people, about 1 in 500.

        Call a healthcare provider right away if you have any of these symptoms, especially if they are new, worse, or worry you:

        • thoughts about suicide or dying
        • attempts to commit suicide
        • new or worse depression
        • new or worse anxiety
        • feeling agitated or restless
        • panic attacks
        • trouble sleeping (insomnia)
        • new or worse irritability
        • acting aggressive, being angry, or violent
        • acting on dangerous impulses
        • an extreme increase in activity and talking (mania)
        • other unusual changes in behavior or mood
        • How can I watch for early symptoms of suicidal thoughts and actions?

          • Pay attetion to any changes, especially sudden changes in mood, behaviors, thoughts, or feelings.
          • Keep all follow-up visits with your healthcare provider as scheduled.
          • Call your healthcare provider between visits as needed, especially if you are worried about your symptoms.

            Do not stop valproic acid oral solution without first talking to a healthcare provider. Stopping valproic acid oral solution suddenly can cause serious problems. Stopping a seizure medicine suddenly in a patient who has epilepsy can cause seizures that will not stop (status epilepticus).

            Suicidal thoughts or actions can be caused by things other than medicines. If you have suicidal thoughts or actions, your healthcare provider may check for other causes.

            What is valproic acid oral solution?

            Valproic acid oral solution is a prescription medicine used alone or with other medicines, to treat:

            • complex partial seizures in adults and children 10 years of age and older
            • simple and complex absence seizures, with or without other seizure types
            • Who should not take valproic acid oral solution?

              Do not take valproic acid oral solution if you:

              • have liver problems
              • have or think you have a genetic liver problem caused by a mitochondrial disorder (e.g. Alpers-Huttenlocher syndrome)
              • are allergic to valproic acid, or any of the ingredients in valproic acid oral solution. See the end of this leaflet for a complete list of ingredients in valproic acid oral solution.
              • have a genetic problem called urea cycle disorder
              • are taking it to prevent migraine headaches and are either pregnant or may become pregnant because you are not using effective birth control (contraception)
              • What should I tell my healthcare provider before taking valproic acid oral solution?

                Before you take valproic acid oral solution, tell your healthcare provider if you:

                • have a genetic liver problem caused by a mitochondrial disorder (e.g. Alpers-Huttenlocher syndrome)
                • drink alcohol
                • are pregnant or breastfeeding. Valproic acid can pass into breast milk. Talk to your healthcare provider about the best way to feed your baby if you take valproic acid oral solution.
                • have or have had depression, mood problems, or suicidal thoughts or behavior
                • have any other medical conditions
                • Tell your healthcare provider about all the medicines you take, including prescription and non-prescription medicines, vitamins, herbal supplements and medicines that you take for a short period of time.

                  Taking valproic acid oral solution with certain other medicines can cause side effects or affect how well they work. Do not start or stop other medicines without talking to your healthcare provider.

                  Know the medicines you take. Keep a list of them and show it to your healthcare provider and pharmacist each time you get a new medicine.

                  How should I take valproic acid oral solution?

                  • Take valproic acid oral solution exactly as your healthcare provider tells you. Your healthcare provider will tell you how much valproic acid oral solution to take and when to take it.
                  • Your healthcare provider may change your dose.
                  • Do not change your dose of valproic acid oral solution without talking to your healthcare provider.
                  • Do not stop taking valproic acid oral solution without first talking to your healthcare provider. Stopping valproic acid oral solution suddenly can cause serious problems.
                  • If you take too much valproic acid oral solution, call your healthcare provider or local Poison Control Center right away.
                  • What should I avoid while taking valproic acid oral solution?

                    • Valproic acid oral solution can cause drowsiness and dizziness. Do not drink alcohol or take other medicines that make you sleepy or dizzy while taking valproic acid oral solution, until you talk with your doctor. Taking valproic acid oral solution with alcohol or drugs that cause sleepiness or dizziness may make your sleepiness or dizziness worse.
                    • Do not drive a car or operate dangerous machinery until you know how valproic acid oral solution affects you. Valproic acid oral solution can slow your thinking and motor skills.
                    • What are the possible side effects of valproic acid oral solution?

                      • See "What is the most important information I should know about valproic acid oral solution?"
                      • Valproic acid oral solution can cause serious side effects including:

                        • Bleeding problems: red or purple spots on your skin, bruising, pain and swelling into your joints due to bleeding or bleeding from your mouth or nose.
                        • High ammonia levels in your blood: feeling tired, vomiting, changes in mental status.
                        • Low body temperature (hypothermia): drop in your body temperature to less than 95°F, feeling tired, confusion, coma.
                        • Allergic (hypersensitivity) reactions: fever, skin rash, hives, sores in your mouth, blistering and peeling of your skin, swelling of your lymph nodes, swelling of your face, eyes, lips, tongue, or throat, trouble swallowing or breathing.
                        • Drowsiness or sleepiness in the elderly.This extreme drowsiness may cause you to eat or drink less than you normally would. Tell your doctor if you are not able to eat or drink as you normally do. Your doctor may start you at a lower dose of valproic acid oral solution.
                        • Call your healthcare provider right away, if you have any of the symptoms listed above.

                          The common side effects of valproic acid oral solution include:

                          • nausea
                          • headache
                          • sleepiness
                          • vomiting
                          • weakness
                          • tremor
                          • dizziness
                          • stomach pain
                          • blurry vision
                          • double vision
                          • diarrhea
                          • increased appetite
                          • weight gain
                          • hair loss
                          • loss of appetite
                          • problems with walking or coordination
                          • These are not all of the possible side effects of valproic acid oral solution. For more information, ask your healthcare provider or pharmacist.

                            Tell your healthcare provider if you have any side effect that bothers you or that does not go away.

                            Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

                            How should I store valproic acid oral solution?

                            • Store valproic acid oral solution at 68° to 77°F (20° to 25°C).
                            • Keep valproic acid oral solution and all medicines out of the reach of children.

                              General information about the safe and effective use of valproic acid oral solution

                              Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use valproic acid oral solution for a condition for which it was not prescribed. Do not give valproic acid oral solution to other people, even if they have the same symptoms that you have. It may harm them.

                              This Medication Guide summarizes the most important information about valproic acid oral solution. If you would like more information, talk with your healthcare provider. You can ask your pharmacist or healthcare provider for information about valproic acid oral solution that is written for health professionals.

                              What are the ingredients in valproic acid oral solution?

                              Active ingredient: valproic acid

                              Inactive ingredients: alchohol (less than 0.05%), artificial cherry flavor, artificial wild cherry flavor, corn syrup solids, FD&C Red No. 40, glycerin, hydrochloric acid, liquid sugar, methylparaben, potassium phosphate dibasic, propylene glycol, purified water, sodium benzoate and sodium hydroxide

                              This Medication Guide has been approved by the U.S. Food and Drug Administration.

                              Rx Only

                              Product No.: 4021

                              Manufactured By:

                              Xttrium Laboratories, Inc.

                              Mount Prospect, IL 60056

                              4021VALINSTA

                              REV. 03-26

* Please review the disclaimer below.